Phenibut

Phenibut

Phenibut is a Soviet-era anti-anxiety compound that crosses the blood-brain barrier and binds to the same receptor system as alcohol and benzodiazepines (GABA-B), with extra activity on the calcium channels that gabapentin and pregabalin work on. People take it for one of three reasons: to take the edge off social anxiety, to sleep, or for the loose, sociable, mildly euphoric feeling at higher doses. It works.
Phenibut has the dependency profile of a benzodiazepine, a slow and unpredictable onset that pushes people to redose and stack doses, and a withdrawal syndrome that at chronic high doses can include seizures, hallucinations, and psychosis. Used once a week or less at a modest dose, it's a tool. Used daily, it becomes a problem faster than almost anything else in the nootropic category, with tolerance documented in as little as a week of regular use and full physical dependence within a few weeks. If you're going to use it keep it occasional.

Deep-dive

Phenibut is β-phenyl-γ-aminobutyric acid, GABA with a phenyl group bolted on so it can actually cross the blood-brain barrier. Structurally it's almost identical to baclofen (the muscle relaxant), differing only by a chlorine atom. Functionally it sits in the gabapentinoid family alongside gabapentin and pregabalin.
The mechanism has two arms. The first is GABA-B agonism, the same receptor baclofen and GHB act on. GABA-B is a metabotropic receptor (it works through second messengers rather than directly opening an ion channel like GABA-A, which is what benzos and alcohol primarily hit), and activating it produces sedation, muscle relaxation, anxiolysis, and at high doses respiratory depression. Phenibut is racemic, meaning it's a 50/50 mix of two mirror-image isomers. Only the R-isomer binds GABA-B. The S-isomer is mostly inert at that receptor. The second arm is binding to the α2-δ subunit of voltage-dependent calcium channels, the same target as gabapentin and pregabalin, which reduces calcium influx in overactive neurons. Both isomers bind here, and the binding affinity for α2-δ is actually about four times higher than for GABA-B. This is why phenibut has a slightly different feel than pure GABA-B agonists like baclofen and produces more cognitive disinhibition and anxiety reduction relative to pure sedation.
At low doses (under 1g), phenibut also mildly increases dopamine, which is where the social, motivated, mildly euphoric quality comes from. At higher doses the GABA-B sedation dominates and the dopamine effect is buried.
Pharmacokinetics matter a lot here. Oral bioavailability is around 63%, plasma half-life is 5.3 hours, and it's excreted mostly unchanged in urine. Onset is the part that catches people out. After oral dosing, effects start at 2 to 4 hours and peak around 4 to 6 hours, with a duration of 15 to 24 hours at recreational doses. This delayed onset is the single most common cause of phenibut overdose. People take a dose, feel nothing at the 90-minute mark, take more, and end up severely sedated 4 hours later when both doses converge. Sublingual or rectal administration shortens onset to roughly 20 to 30 minutes but does nothing for safety.
Anxiety and sleep. The clinical evidence base is mostly Russian and mostly old. A systematic review of clinical trials and case reports concluded that at therapeutic doses (roughly 250 mg to 2 g per day), phenibut is well tolerated with adverse events in only 5.66% of patients, somnolence being most common at 1.89%. Russian and Latvian trials have used it for adjustment disorder, anxiety in cardiovascular and gastrointestinal patients, alcohol withdrawal, and post-stroke recovery, with positive results, though the methodological quality is generally weak by modern standards. The subjective effect on social anxiety, in particular, is what people actually use it for, and is consistently reported.
Nootropic claims. Despite being marketed as a cognitive enhancer, evidence that phenibut improves cognition in healthy people is thin. Russian research describes it as cognition-supporting in the context of fatigue, asthenia, or recovery from neurological insult, not as a performance-enhancing nootropic in the modern sense. Studies in traumatic brain injury models show R-phenibut has mitochondrial-protective effects, but this is animal work in injury contexts, not a basis for daily use in healthy adults.
The dependence profile is the real story. A 2024 systematic review of phenibut withdrawal cases found the average dependent user was on 13.6 g/day (range 1.5 to 28.5 g/day), most were male (87%), and most had a history of anxiety, depression, or substance use. Tolerance can develop within a week of regular use. Withdrawal symptoms include severe rebound anxiety, insomnia, tachycardia, hypertension, agitation, hallucinations, psychosis, and in severe cases seizures, and the syndrome resembles benzodiazepine or alcohol withdrawal. Standard medical management is a baclofen taper (because baclofen is structurally similar and hits the same GABA-B receptor) at roughly 10 mg of baclofen per 1 g of phenibut, sometimes with adjunctive benzodiazepines or phenobarbital. Severe cases require inpatient detox and recovery can take months.
The mechanism of dependence appears to be GABA-B receptor downregulation with repeated agonism, similar to what happens with chronic benzodiazepine exposure at GABA-A. Once the receptors have downregulated, removing the drug leaves the system in a hyperexcitable state until receptors normalise, which takes weeks to months.
Women. There's almost no female-specific phenibut research. The Russian clinical literature includes mixed-sex samples without separating outcomes, and the systematic review on withdrawal cases skewed heavily male (87%), which reflects who gets into trouble with it rather than who responds to it. A few practical points apply. GABA-B receptor density and function vary across the menstrual cycle in ways that parallel sex hormone fluctuations, so subjective intensity may shift across the cycle. Women generally have lower body weight and slightly lower volumes of distribution, which means online discussions widely recommend lower starting doses for women of around 100 to 250 mg, though this is empirical rather than research-backed. The first reported neonatal phenibut withdrawal case involved a mother who used 12 g/day during pregnancy, with the neonate requiring lorazepam to manage withdrawal at birth. Pregnancy and breastfeeding are absolute contraindications.
Older adults. A larger fraction of the dose reaches the brain in the very young and elderly, and clearance is slower. If used at all over 60, doses should be markedly lower (start at 100 to 250 mg) and frequency much more conservative. The cognitive impairment and fall risk on day-after sedation make this group particularly vulnerable.
The cleanest comparison. Phenibut sits between alcohol, benzodiazepines, and gabapentin in its effect profile. The risk of serious harm with occasional, modest, single-source-quality use is low. The risk of serious harm with regular use is high, and rises steeply once you cross into daily dosing or doses above 1 to 2 g. The cases that end up in emergency departments are almost always either chronic high-dose users in withdrawal, or people who combined it with alcohol, opioids, or benzodiazepines. Both of those are avoidable.

Dosage:

  • Anxiolytic / social dose: 250-500 mg, taken 3-4 hours before you need the effect. This is the dose most people should start at and most people should stay at
  • Higher dose for sleep or stronger effect: 500-1000 mg. Above 1 g you're firmly in the territory where dependence develops faster and side effects (next-day grogginess, GI upset, paradoxical anxiety) climb sharply
  • Hard ceiling: Don't exceed 1 g in a single dose or 2 g in a day. This isn't a productivity number, it's a safety number. Russian clinical use stays within 250 mg to 2 g per day total
  • Women, smaller adults, anyone over 60: Start at 100-250 mg. Wait the full 4 hours before considering more. Lower body weight and slower clearance mean the same dose hits harder
  • Frequency is the most important number on this page. Once a week or less. Twice a week occasionally. Never two days in a row, and never a daily ritual. People who use it 3+ times a week reliably end up with tolerance within weeks and dependence shortly after
  • Timing: Take it 3-4 hours before you actually want the effect. If you're using it for an evening event, dose mid-afternoon. If for sleep, dose with dinner. Onset is slow, do not redose if you don't feel it at the 90-minute mark, this is how most overdoses happen
  • Empty stomach speeds onset slightly but doesn't change peak. Sublingual is faster (20-30 minutes) but doesn't make it safer
  • Forms: Phenibut HCl is the standard, slightly acidic, tastes bad in water. Phenibut FAA (free amino acid) is the less-acidic free base form, easier on the stomach, but onset and effect are otherwise the same. Stick with HCl from a vendor that publishes third-party purity testing, the FDA review of marketed products found dosing on labels ranging from zero to over 1,100 mg per serving with significant variability
  • Stacks to avoid: Alcohol, benzodiazepines, opioids, GHB, barbiturates, and other gabapentinoids. The combination with any other CNS depressant produces additive respiratory depression and is the single most common factor in serious phenibut intoxications and the few documented deaths

Here's what you can expect:

At 250-500 mg, somewhere between 3 and 5 hours after dosing you should notice a calm, slightly buoyant mood, easier conversation, less self-monitoring, and an absence of anxious tightness in the chest or throat. It doesn't feel sedating at this dose, more like a pleasant social lubricant without the cognitive blur of alcohol. Sleep that night tends to come more easily and feel deeper. The next morning is usually fine.
At 500-1000 mg, the effect is stronger, more obviously euphoric, and starts to shade into mild sedation and motor clumsiness. Some people get a noticeable hangover the next day, foggy, lethargic, occasional rebound anxiety. This is the dose where the trade-off starts to shift.
Above 1 g you're in territory where the next 24-36 hours can be unpleasant, where your judgment about whether to redose gets unreliable, and where you start training your brain to expect this level of GABA-B activation regularly. People who chase the higher dose are the ones who end up dependent.
With repeated use over weeks, the pleasant social quality fades faster than the sedative effect. People often report that the magic of the first few uses doesn't return, but the compulsion to keep using does. This is the classic tolerance trajectory of GABA-ergic drugs and it's the warning sign to stop.

Side effects & risks:

  • Next-day grogginess and rebound anxiety are the most common acute side effects, especially above 500 mg. The long half-life means residual sedation through the following day is normal at higher doses
  • GI discomfort, nausea, headache, dizziness are dose-dependent. The acidic HCl form can also irritate the stomach if taken without food or water
  • Paradoxical agitation, irritability, or anxiety can occur, particularly during the onset window or as the dose wears off. More common in people prone to anxiety
  • Dependence develops faster than most people expect. Tolerance can build within a week of regular use. Daily use for a few weeks is usually enough to produce a meaningful withdrawal syndrome on cessation. This is the single biggest risk
  • Withdrawal at chronic high doses is medically serious. Symptoms include severe rebound anxiety, insomnia, tachycardia, hypertension, agitation, tremor, visual and auditory hallucinations, psychosis, and in severe cases seizures. The pattern resembles benzodiazepine or alcohol withdrawal and can require hospitalisation. Do not abruptly stop after sustained daily use, taper slowly, and consider medical supervision if you've been on more than 1-2 g/day for more than a few weeks
  • Combination with other CNS depressants is the main cause of serious harm. Phenibut plus alcohol, benzodiazepines, opioids, GHB, or barbiturates produces additive respiratory depression. Most documented phenibut hospitalisations and the few deaths involve a combination, not phenibut alone
  • Overdose at single doses above several grams can cause severe sedation, unresponsiveness, vomiting, low blood pressure, kidney impairment, and at very high doses (above 7 g) fatty liver degeneration. There is no specific antidote. Management is supportive
  • Driving and machinery: Don't, for at least 12-18 hours after a dose. The effect lasts longer than people think and motor coordination can be subtly impaired well after the subjective high is gone
  • Mental health history: People with a history of substance use disorder, anxiety, or depression are over-represented in dependence cases. If that's you, the risk-reward is worse than for the general population
  • Drug testing: Phenibut occasionally produces a false positive for benzodiazepines on standard immunoassay screens. It's detectable in urine for days to weeks depending on use pattern
Sold online as a research chemical or unregulated supplement in most countries. Banned or controlled in Australia, Hungary, Italy, Lithuania, and several others. The FDA has stated it does not meet the definition of a dietary ingredient and products marketing it as one are misbranded.